AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise

AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...

AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot

AbbVie Inc. targets $38B in Skyrizi and Rinvoq sales by 2030, a 3% dividend yield, and 7.7% EPS growth via acquisitions.

AbbVie earnings beat Wall Street expectations. The stock is falling anyway

AbbVie posts better-than-expected earnings but revenue declines across certain business lines.

Where Will AbbVie Be in 5 Years?

A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.

AbbVie Balances Drug Affordability Deal With R&D And Patient Growth Plans

AbbVie (NYSE:ABBV) agreed to a three year voluntary drug affordability deal with the US government, paired with a pledge to ...
StockStory.org on MSN

AbbVie’s (NYSE:ABBV) Q4 CY2025 beats on revenue

Pharmaceutical company AbbVie (NYSE:ABBV) reported Q4 CY2025 results , with sales up 10% year on year to $16.62 billion. Its ...

Better Long-Term Buy: This Emerging Player or the Industry Leader?

The choice between the two might come down to each investor's goals and risk tolerance.
AOL

Is AbbVie Stock a Buy?

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while raising ...

2 Healthcare Dividend Stocks That are Just What the Doctor Ordered

AbbVie and Medtronic have a long history of raising their dividends and continue to have healthy free cash flow for further dividend growth.
Crain's Chicago Business

Despite $3.5B impairment charge on failed Cerevel drug, AbbVie still sees potential

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie leaders are “disappointed” with poor results from a ...